1. Home
  2. XLO vs KORE Comparison

XLO vs KORE Comparison

Compare XLO & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • KORE
  • Stock Information
  • Founded
  • XLO 2016
  • KORE 2003
  • Country
  • XLO United States
  • KORE United States
  • Employees
  • XLO N/A
  • KORE N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • KORE Telecommunications Equipment
  • Sector
  • XLO Health Care
  • KORE Consumer Discretionary
  • Exchange
  • XLO Nasdaq
  • KORE Nasdaq
  • Market Cap
  • XLO 40.9M
  • KORE 45.0M
  • IPO Year
  • XLO 2021
  • KORE N/A
  • Fundamental
  • Price
  • XLO $0.82
  • KORE $3.81
  • Analyst Decision
  • XLO Buy
  • KORE Hold
  • Analyst Count
  • XLO 2
  • KORE 2
  • Target Price
  • XLO $3.00
  • KORE $2.75
  • AVG Volume (30 Days)
  • XLO 469.6K
  • KORE 31.1K
  • Earning Date
  • XLO 11-07-2025
  • KORE 11-12-2025
  • Dividend Yield
  • XLO N/A
  • KORE N/A
  • EPS Growth
  • XLO N/A
  • KORE N/A
  • EPS
  • XLO N/A
  • KORE N/A
  • Revenue
  • XLO $15,001,000.00
  • KORE $285,636,000.00
  • Revenue This Year
  • XLO $519.70
  • KORE $4.46
  • Revenue Next Year
  • XLO $44.57
  • KORE $5.94
  • P/E Ratio
  • XLO N/A
  • KORE N/A
  • Revenue Growth
  • XLO 536.45
  • KORE 0.24
  • 52 Week Low
  • XLO $0.62
  • KORE $1.10
  • 52 Week High
  • XLO $1.70
  • KORE $4.88
  • Technical
  • Relative Strength Index (RSI)
  • XLO 57.82
  • KORE 78.03
  • Support Level
  • XLO $0.73
  • KORE $2.99
  • Resistance Level
  • XLO $0.85
  • KORE $3.17
  • Average True Range (ATR)
  • XLO 0.05
  • KORE 0.19
  • MACD
  • XLO 0.00
  • KORE 0.06
  • Stochastic Oscillator
  • XLO 65.97
  • KORE 97.91

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About KORE KORE Group Holdings Inc.

Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.

Share on Social Networks: